Lipoic Acid and Omega-3 Fatty Acids vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.0769 | 0.0214 | 0.241 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0 | 0.0000000000000000139 | 0.121 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | 0.0769 | -0.0559 | 0.241 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | ClinicalTrials.gov | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | ClinicalTrials.gov | |||
| Number needed to harm, for one more participant with a serious adverse event on Lipoic Acid and Omega-3 Fatty Acids than on Placebo | 13 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Lipoic Acid and Omega-3 Fatty Acids | lipoic acid and omega-3 fatty acids~Alpha lipoic acid and omega-3 fatty acids: alpha lipoic acid as racemic form at 1,200 mg per day omega-3 fatty acids as fish oil concentrate containing a daily dose of 1.35 grams docosahexanoic acid and 1.95 grams of eicosapentaenoic acid | 2 | 26 | EG000 | ClinicalTrials.gov |
| Group 2 | Placebo | placebo oil and placebo lipoic acid~Placebo: placebo lipoic acid and placebo oil | 0 | 28 | EG001 | ClinicalTrials.gov |
Harm 2
| Field | Value | Source |
|---|---|---|
| What it counts | Total, serious adverse events | ClinicalTrials.gov |
| Time frame | 12 weeks | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis | ClinicalTrials.gov |
| NCT number | NCT02133664 | ClinicalTrials.gov |
| Phases | PHASE1, PHASE2 | ClinicalTrials.gov |
| Conditions | Multiple Sclerosis, Cognition | ClinicalTrials.gov |
| Interventions | lipoic acid and omega-3 fatty acids, Placebo | ClinicalTrials.gov |
| Lead sponsor | Oregon Health and Science University | ClinicalTrials.gov |
| Results first posted | 2017-05-03 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT02133664?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.